STOCKHOLM, October 15, 2014 /PRNewswire/ --
Episurf Medical has secured CE certification of its new product, Episealer® Trochlea, intended to treat cartilage- and bone injury behind the patella. Certification allows the company to commence the marketing and sales process of the product in Europe.
"Osteoarthritis is a growing problem and there is a major need for new types of therapy. We now have two mutually complementary products on the market to address this growing need with our unique technology," commented Nina Bake, CEO of Episurf Medical.
Episurf Medical's new product, Episealer® Trochlea, is based on the company's individually customized implant technology. It is intended to treat cartilage and bone defects in the area behind the patella (kneecap). The product will now be available through a Controlled Product Launch (CPL). The company's first product, Episealer® Femoral Condyle, has been in a CPL for the past year.
"Over the past year, we've affiliated major clinics and key opinion leaders to the ongoing CPL of Episealer® Femoral Condyle. Accordingly, we've already established a strong network of valuable contacts and launched a model that we can leverage on to bring this new product to market," continued Nina Bake.
Fifteen clinics in nine countries have now affiliated to the CPL, which commenced in 2013. Recently, the company has recruited several experienced international marketing and sales professionals who now have another innovative product and technique to improve patients' lives and add to the surgeon's choice.
In surgeries performed to date, patients have rapidly regained mobility and relief from previous pain. Episurf Medical's growing product range is able to address and treat the increasing number of patients experiencing knee pain and limited mobility.
Episurf Medical has developed unique, patented technology to manufacture personalized implants and surgical tools to treat injury to human joints. The implants replace areas of damaged cartilage and skeletal tissue.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® individually customized implants and Epiguide® surgical drill guides are in development for treating localized cartilage and bone injuries in joints. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm.
For more information:
Nina Bake, CEO of Episurf Medical AB (publ)
Tel: +46-(0)73-612-5563, e-mail: firstname.lastname@example.org
SOURCE Episurf Medical